CS Diagnostics Corp 最大收入來源為 Medical Technology,在最近的收益報告中收入為 110,911。就地區而言,United States 是 CS Diagnostics Corp 的主要市場,收入為 110,911。
CS Diagnostics Corp 是否盈利?
無,根據最新的財務報表,CS Diagnostics Corp 的淨損失為 $0
CS Diagnostics Corp 有負債嗎?
無,CS Diagnostics Corp 的負債為 0
CS Diagnostics Corp 的流通股有多少?
CS Diagnostics Corp 的總流通股為 0
關鍵數據
前收市價
--
開盤價
--
當日範圍
-
52週區間
-
交易量
--
平均成交量
--
股息收益率
--
每股盈餘 (TTM)
--
市值
--
什麼是 CSDX?
CS Diagnostics Corp. is a medical distribution company that provides the advancing patient care through innovative solutions. The firm is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. The company is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. The company includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.